证券代码：002044 证券简称：美年健康 公告编号：2025-069 一、本次会议召开基本情况 1、股东大会届次：公司 2025 年第二次临时股东大会。 2、股东大会召集人：公司第九届董事会第十三次（临时）会议决议召开， 由公司董事会召集。 3、会议召开的合法、合规性：本次股东大会的召集、召开及审议事项符合 《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所股票上 市规则》等法律、行政法规及《公司章程》等规定，提案内容明确并在法定期限 内公告。 4、会议召开的日期、时间： 美年大健康产业控股股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 美年大健康产业控股股份有限公司（以下简称"公司"）2025 年第二次临时 股东大会现场会议的召开地点为上海市静安区灵石路697号健康智谷9号楼三楼 公司会议室，敬请投资者特别留意。 根据公司于 2025 年 9 月 26 日召开的第九届董事会第十三次（临时）会议， 定于 2025 年 10 月 14 日召开公司 2025 年第二次临时股东 ...

证券代码：002044 证券简称：美年健康 公告编号：2025-067 美年大健康产业控股股份有限公司 第九届董事会第十三次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本议案尚需提交公司股东大会审议，并须经出席会议的股东所持有效表决权 的三分之二以上通过。 2、审议并通过《关于修订和新制定公司治理相关制度的议案》 为贯彻落实《中华人民共和国公司法》《关于新<公司法>配套制度规则实施相 关过渡期安排》《上市公司章程指引》《深圳证券交易所股票上市规则》《深圳证券 一、董事会会议召开情况 美年大健康产业控股股份有限公司（以下简称"公司"）第九届董事会第十三 次（临时）会议于 2025 年 9 月 19 日以电子发送等形式发出会议通知，会议于 2025 年 9 月 26 日上午 9:30 以通讯方式召开。应出席本次会议的董事为 9 名，实际出 席会议的董事为 9 名。会议由公司董事长俞熔先生主持，公司监事及高级管理人 员列席了会议。本次会议的出席人数、召开表决程序、议事内容均符合《中华人 民共和国公司法》《公司章程》等有关规定。 二、董事会会 ...

Core Viewpoint - The company is leveraging AI technology to enhance the efficiency, accuracy, and personalization of health check-up services, addressing customer pain points and transforming the traditional health check-up model into a comprehensive health management platform [1][10]. Group 1: AI Integration and Service Upgrades - The company has launched a digital management platform called "Bian Que SAAS," which digitizes and streamlines the entire health check-up process from appointment scheduling to report generation, significantly improving efficiency and accuracy [2][3]. - AI-driven pre-appointment systems allow customers to book check-ups in just 30 seconds, optimizing appointment times based on real-time analysis of customer flow [2][3]. - The implementation of intelligent navigation during check-ups helps customers avoid long wait times by dynamically planning the most efficient route through the various examination stations [3]. Group 2: Personalized Health Screening - The company offers personalized health screening plans based on individual assessments that consider factors such as gender, age, and family health history, ensuring targeted and effective health checks [4][5]. - A combination of standardized packages and customizable options allows each customer to receive a tailored health check-up plan, enhancing the relevance of the services provided [4][5]. Group 3: Quality Control and Accuracy - The company has established comprehensive AI quality control measures throughout the health check-up process, ensuring the reliability and accuracy of results [6]. - Continuous optimization of operational procedures and strict adherence to standard operating procedures (SOP) by medical staff further enhance the accuracy of health assessments [4][6]. Group 4: Comprehensive Health Management - The company is expanding its services beyond traditional check-ups to include full-cycle health management, integrating prevention, treatment, and insurance services [7][9]. - New health management tools and AI-driven products are being introduced to support personalized health management, particularly in chronic disease prevention and weight management [7][9]. Group 5: Post-Check-Up Services - The company provides dual report interpretation services, combining AI analysis with professional medical consultations to ensure customers understand their health reports and receive personalized health management advice [8]. - A range of post-check-up services, including specialized insurance products for customers with abnormal results, is being offered to enhance customer support and care [9]. Group 6: Future Vision - The company aims to redefine the value of health check-ups by integrating AI technology throughout the entire customer journey, transitioning from a one-time service to a long-term health management partnership [10]. - The commitment to continuous improvement in service quality and the expansion of AI applications is positioned to lead the health check-up industry towards innovation and enhanced customer care [10].

9月24日美年健康大宗交易一览 证券时报·数据宝统计显示，美年健康今日收盘价为5.04元，上涨1.20%，日换手率为1.06%，成交额为 2.06亿元，全天主力资金净流入765.51万元，近5日该股累计下跌4.18%，近5日资金合计净流出1.24亿 元。 两融数据显示，该股最新融资余额为9.96亿元，近5日减少512.48万元，降幅为0.51%。 据天眼查APP显示，美年大健康产业控股股份有限公司成立于1991年01月22日。注册资本391425.3923 万人民币。（数据宝） 美年健康9月24日大宗交易平台共发生2笔成交，合计成交量99.96万股，成交金额503.80万元。成交价格 均为5.04元。从参与大宗交易营业部来看，机构专用席位共出现在2笔成交的买方或卖方营业部中，合 计成交金额为503.80万元，净买入503.80万元。 进一步统计，近3个月内该股累计发生39笔大宗交易，合计成交金额为3.35亿元。 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | ...

9月24日，美年健康大宗交易成交99.96万股，成交额503.8万元，占当日总成交额的2.39%，成交价5.04 元，较市场收盘价5.04元持平。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | (万股/万份) | | | | | 2025-09-24 | 002044 | 美年健康 | 5.04 | 52.94 | 266.82 机构专用 | | 中信证券股份有限 | | | | | | | | | 公司大连分公司 | | 2025-09-24 | 002044 | 美年健康 | 5.04 | 47.02 | 236.98 机构专用 | | 华泰证券股份有限 | | | | | | | | | 公司上海长宁区凯 | | | | | | | | | 旋路证券营业部 | ...

Core Insights - The strategic partnership between Meinian Health Group and Beijing Guoping Innovation Medical Technology Co., Ltd. aims to create a health management platform that integrates technology, medical resources, and corporate service needs, focusing on health check-ups, chronic disease rehabilitation, and health management services for enterprises and individuals [1][3]. Group 1: Meinian Health Group's Initiatives - Meinian Health Group emphasizes high medical quality by aligning with top-tier hospitals and aims to transition health management from basic screening to precise intervention [3]. - The company is leveraging "big data + AI" to establish a personal health data center and has developed three smart systems: Bianque SAAS, LIS, and PACS, along with the AI health assistant "Health Xiaomei" [3]. - The collaboration with Guoping Innovation Medical is seen as a practical step towards comprehensive health management throughout the entire life cycle, enhancing the health management of entrepreneurs [3]. Group 2: Guoping Innovation Medical's Perspective - The founder of Guoping Innovation Medical highlighted four core factors for the partnership: personal medical experiences, Meinian's expertise in health management, the goal of safeguarding entrepreneurs' health, and contributing to the "Healthy China" initiative [5]. - The collaboration aims to enhance the professionalism and credibility of the health management platform [5]. Group 3: Strategic Cooperation and Platform Launch - The signing of the strategic cooperation agreement and the unveiling of the "Guoping Entrepreneur Health Management Base" marks the official establishment of a specialized platform focused on the health management of entrepreneurs [8]. - This partnership represents a resource integration and an innovative exploration of high-end health management service models, targeting the health needs of high-end demographics [8].

Group 1 - The core viewpoint of the article is the strategic partnership between Meinian Health Group and Beijing Guoping Innovation Medical Technology Co., Ltd. to enhance health management services [1] - The collaboration will focus on areas such as health check-ups, chronic disease rehabilitation, medical care, and health management services for both enterprises and individuals [1]

Core Insights - The strategic partnership between Meinian Health Group and Beijing Guoping Innovation Medical Technology Co., Ltd. aims to create a health management platform that integrates technology, medical resources, and corporate service needs, focusing on health check-ups, chronic disease rehabilitation, and health management services for enterprises and individuals [1][5][12] Group 1: Partnership Details - The collaboration is marked by the establishment of the "Guoping Entrepreneur Health Management Base," which will focus on personalized health screening, comprehensive health management, and high-end medical resource integration [5][11] - The partnership is a response to the uneven distribution of medical resources in China and aims to address the urgent health management needs of entrepreneurs [7][13] Group 2: Key Figures and Leadership - Key figures present at the signing ceremony included Meinian Health Group's Vice Chairman Guo Meiling, President Xu Tao, and Guoping's Chairman Liu Xiaoming, highlighting the importance of leadership in this initiative [3][11] - The first batch of membership cards was issued to entrepreneurs, marking the commencement of services at the health management base [12] Group 3: Technological Integration - Meinian Health is leveraging big data and AI technologies to build the largest personal health data center in China, developing smart systems to enhance health management services [5][12] - The collaboration will utilize AI-driven health management tools to create a seamless service loop from health check-ups to interventions and follow-ups [5][13] Group 4: Health Challenges and Solutions - The initiative addresses significant health challenges faced by entrepreneurs, including the need for urgent medical access and personalized health management [13] - The health management base will provide a range of services, including health assessments, emergency hospitalization coordination, and 24/7 health management support [13]

Core Insights - The collaboration between Meinian Health Group and Beijing Guoping Innovative Medical Technology Co., Ltd. focuses on health management for entrepreneurs, aligning with the "Healthy China" strategy [1] - The partnership aims to create a health management platform that integrates resources and addresses pain points in the health sector [1] - The initiative is marked by the signing of agreements and the unveiling of the Guoping Entrepreneur Health Management Base, which signifies the launch of the platform [1] Summary by Sections Collaboration Details - The strategic cooperation was highlighted during a signing ceremony in Beijing, emphasizing the theme "Empowering Health with Technology" [1] - Key figures from both companies, including Meinian Health's Vice Chairman Guo Meiling and President Xu Tao, attended the event [1] Objectives and Benefits - The collaboration is based on four core factors, including the recognition of the platform's value in resource integration and problem-solving by medical and entrepreneur representatives [1] - The partnership aims to provide comprehensive lifecycle services for entrepreneurs, addressing their unique health challenges through multi-dimensional health management services [1] Future Implications - This collaboration is expected to set a benchmark in the high-end health management sector, safeguarding the health of high-end populations and injecting health momentum into China's development [1]

Core Insights - The report from Guosheng Securities indicates that Meinian Health's net profit attributable to shareholders for the first half of the year was -221 million yuan, a year-on-year decrease of 2.59% [1] - In Q2 2025, the net profit attributable to shareholders was 53.98 million yuan, reflecting a year-on-year decline of 23.81% [1] Business Performance - The company achieved a dual-driven model of individual and group health check-ups, with a total of 9.55 million visits (including affiliated hospitals) in the first half of the year, of which 6 million visits were from controlled hospitals [1] - The group health check-up business remains a revenue pillar, accounting for 67% of total revenue, supported by deep engagement with clients in six major industries: banking, telecommunications, public security, energy, electricity, and education [1] Operational Metrics - As of June 30, 2025, the company had 566 branches covering over 30 provinces (autonomous regions, and municipalities), with 304 of these being controlled health check-up branches [1] - In H1 2025, the company managed to reduce sales expenses to 982 million yuan, a year-on-year decrease of 8.75%, and management expenses to 415 million yuan, a year-on-year decrease of 0.50%, indicating effective cost control and the release of operational leverage [1] Future Outlook - Due to the decline in performance in H1 2025 and the anticipated recovery time for the health check-up market demand, the company has adjusted its previous earnings forecast while maintaining a "buy" rating [1]